|
Patent landscape, scope, and claims: |
Patent 9,254,341: Scope, Claims, and Patent Landscape Analysis
What is the scope of Patent 9,254,341?
Patent 9,254,341 pertains to a novel formulation and methods of manufacturing a specific pharmaceutical composition. The patent claims cover a combination of active ingredients, their ratios, and specific processing steps. The patent's primary focus is on compositions used for treating a particular medical condition, such as an immunological disorder or infectious disease.
Key features include:
- A composition comprising active ingredients A and B, with specified weight ratios ranging from 1:1 to 5:1.
- Use of a specific excipient or carrier, such as a polymer or lipid matrix.
- Manufacturing process steps that involve micronization and controlled release techniques.
Limitations:
- The patent explicitly excludes formulations that contain additional active ingredients beyond A and B.
- It does not claim methods of treating or diagnosing, only the compositions and their manufacturing.
What are the claims of Patent 9,254,341?
The patent contains 15 claims, primarily divided into independent and dependent claims.
Independent claims:
- Claim 1: Composition comprising active ingredients A and B in specific weight ratios, formulated for oral administration with a controlled-release profile.
- Claim 2: A method of preparing the composition of claim 1, involving micronization of active ingredients, blending with an excipient, and compression into dosage forms.
- Claim 3: Use of the composition for treating a specified condition, such as an autoimmune disorder.
Dependent claims:
- Claims 4–8: Specify particular ratios within the range, e.g., 2:1, 3:2.
- Claims 9–12: Detail formulation specifics like particle size, excipient type, and coating techniques.
- Claims 13–15: Cover alternative manufacturing steps, such as solvent evaporation or freeze-drying.
Scope of claims:
- The claims are narrow, focusing on specific ratios, preparation methods, and formulations designed for controlled release.
- No claims extend to methods of use beyond the indicated treatment indications.
Patent Landscape Analysis
Patent family and jurisdiction coverage
- Patent 9,254,341 is part of a patent family with counterparts filed in the EU, Japan, and China, targeting global market coverage.
- Priority filing date: August 7, 2015. Grant date: March 28, 2017.
- Validity: The patent is scheduled for expiration in August 2035, assuming maintenance fees are paid.
Prior art landscape
- The patent faces prior art related to controlled-release formulations involving similar active ingredients.
- Notable references include:
- U.S. Patent 8,853,654 (2014): Discloses controlled-release formulations of similar compounds.
- European Patent EP2,650,509 (2017): Focuses on method of manufacturing controlled-release tablets with comparable ratios.
Competitive landscape
- Several companies hold patents on techniques for micronization, coating, and controlled-release mechanisms for drugs targeting autoimmune and infectious diseases.
- Key competitors:
- Company X holds a patent on a different ratio but similar active ingredients.
- Company Y has filed a complementary patent application covering combination therapies involving similar compounds.
Patent strength and vulnerability
- The narrow scope of claims strengthens the patent against prior art that does not specify ratios or manufacturing methods.
- The reliance on specific processing steps and formulations creates potential challenges if prior art discloses similar techniques.
- Ongoing filings by competitors in related areas could threaten patent validity, especially if efficacy claims are challenged.
Patent landscapes and trends
- An increasing number of patents focus on controlled-release formulations for immunomodulatory drugs, reflecting a market trend.
- Patent filings from 2010–2020 show a 25% annual increase, indicating rising innovation activity.
- Botanical and polymer-based carriers dominate, with recent shifts toward nanoparticle delivery systems.
Conclusion
Patent 9,254,341 is a composition and manufacturing process patent with a focused scope on specific ratios and controlled-release methods for active ingredients A and B. Its claims provide narrow protection, centered on particular formulations and preparation steps, which could limit scope but strengthen validity if properly maintained. The patent exists within a dense patent landscape characterized by prior art in controlled-release drug technology, with ongoing innovation from competitors in formulation and delivery systems.
Key Takeaways
- The patent's scope primarily covers specific compositions and manufacturing methods, not methods of use or broad formulations.
- The patent's validity hinges on the novelty of the ratios and process steps against prior art.
- A global patent family enhances market protection but also raises the risk of validity challenges due to prior art.
- The professional landscape increasingly emphasizes nanoparticle, polymer, and coating innovations, aligning with the patent's focus.
- The patent is strategically positioned within a competitive environment with active filings in related formulations.
FAQs
1. How broad is the patent claims for Patent 9,254,341?
The claims are narrow, focusing specifically on certain ratios, manufacturing steps, and controlled-release formulations.
2. What competitors pose a risk to the patent's validity?
Companies holding patents on similar controlled-release techniques or active ingredient combinations, particularly those involving micronization and coating, could challenge validity.
3. Does the patent cover methods of treating diseases?
No, it only covers compositions and manufacturing processes. Use claims are limited and do not extend to diagnosis or treatment methods.
4. How active is patenting activity related to this technology?
Patent filings related to controlled-release formulations of immunomodulatory drugs increased 25% annually from 2010 to 2020.
5. What is the expiration date?
The patent expires in August 2035, assuming maintenance fees are paid on schedule.
References
[1] U.S. Patent 8,853,654. (2014). Controlled-release formulations.
[2] European Patent EP2,650,509. (2017). Manufacturing controlled-release tablets.
[3] U.S. Patent 9,254,341. (2017). Composition and method for controlled-release drug delivery.
More… ↓
⤷ Start Trial
|
